These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Synthesis of 5-chloro-N-aryl-1H-indole-2-carboxamide derivatives as inhibitors of human liver glycogen phosphorylase a. Onda K, Suzuki T, Shiraki R, Yonetoku Y, Negoro K, Momose K, Katayama N, Orita M, Yamaguchi T, Ohta M, Tsukamoto S. Bioorg Med Chem; 2008 May 15; 16(10):5452-64. PubMed ID: 18434170 [Abstract] [Full Text] [Related]
18. Nicotinic acids: liver-targeted SCD inhibitors with preclinical anti-diabetic efficacy. Powell DA, Black WC, Bleasby K, Chan CC, Deschenes D, Gagnon M, Gordon R, Guay J, Guiral S, Hafey MJ, Huang Z, Isabel E, Leblanc Y, Styhler A, Xu LJ, Zhang L, Oballa RM. Bioorg Med Chem Lett; 2011 Dec 15; 21(24):7281-6. PubMed ID: 22047692 [Abstract] [Full Text] [Related]
19. Anthranilimide based glycogen phosphorylase inhibitors for the treatment of type 2 diabetes. Part 3: X-ray crystallographic characterization, core and urea optimization and in vivo efficacy. Thomson SA, Banker P, Bickett DM, Boucheron JA, Carter HL, Clancy DC, Cooper JP, Dickerson SH, Garrido DM, Nolte RT, Peat AJ, Sheckler LR, Sparks SM, Tavares FX, Wang L, Wang TY, Weiel JE. Bioorg Med Chem Lett; 2009 Feb 15; 19(4):1177-82. PubMed ID: 19138846 [Abstract] [Full Text] [Related]